<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099303</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CTP-DTcP-Ⅰ</org_study_id>
    <nct_id>NCT04099303</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .</brief_title>
  <acronym>PCTDTcP</acronym>
  <official_title>A Randomized,Blind, Positive-controlled Phase I Clinical Trial to Preliminary Evaluate the Safety of DTcP Vaccine in Healthy Children Aged Between 2 Months and 6 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pertussis, diphtheria and tetanus are seriously infectious diseases in children. Since using
      of the vaccine targeted the three components, it greatly reduced incidence of the three kinds
      of diseases. The Purpose of this study is to preliminary evaluate the safety of DTcP compared
      to adsorbed diphtheria and tetanus combined vaccine （DT），Diphtheria-tetanus-acellular
      pertussis vaccine（DTaP） or PENTAXIM（DTaP-IPV-Hib） in participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive a single booster dose of DTcP or a single booster dose of
      local DT in 4 to 6 years old ,a singel booster dose of DTcP or a single booster dose of DTaP
      in 18 to 24 months, three basic doses of DTcP or three doses of DTaP/ DTaP-IPV-Hib in 2 to 6
      months.Safety profile will be assessed in all subjects up to Day 30 post vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety items of adverse reactions</measure>
    <time_frame>within 30 minutes post-vaccination</time_frame>
    <description>Occurrence of adverse reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety items of adverse reactions</measure>
    <time_frame>within 7 days post-vaccination</time_frame>
    <description>Occurrence of adverse reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety items of SAE: Occurrence of SAE</measure>
    <time_frame>within 360 days post-vaccination</time_frame>
    <description>Occurrence of SAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety itmes of laboratory measures: Occurrence of abnormal changes of laboratory measures</measure>
    <time_frame>the fourth day post-vaccination</time_frame>
    <description>Occurrence of abnormal changes of laboratory measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety items of adverse reactions</measure>
    <time_frame>within 8-30 days post-vaccination</time_frame>
    <description>Occurrence of adverse reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety items of adverse reactions</measure>
    <time_frame>within 30 days post-vaccination</time_frame>
    <description>Occurrence of adverse reactions</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Vaccine 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of DTaP aged 4 to 6 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of DT aged 4 to 6 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of DTcP aged 18 to 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of DTaP aged 18 to 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of DTcP at 3,4,5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 3B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received three doses of DTaP at 3,4,5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 3C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received three doses of DTaP-IPV-Hib at 3,4,5 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of DTcP at 2,3,4 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 4B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received three doses of DTaP-IPV-Hib at 2,3,4 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine 4C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of DTcP at 2,4,6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed</intervention_name>
    <description>0.5 mL, Intramuscular Other Name: DTcP</description>
    <arm_group_label>Vaccine 1A</arm_group_label>
    <arm_group_label>Vaccine 2A</arm_group_label>
    <arm_group_label>Vaccine 3A</arm_group_label>
    <arm_group_label>Vaccine 3B</arm_group_label>
    <arm_group_label>Vaccine 4A</arm_group_label>
    <arm_group_label>Vaccine 4C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria and Tetanus Combined Vaccine, Adsorbed</intervention_name>
    <description>2mL, Intramuscular Other Name: DT</description>
    <arm_group_label>Vaccine 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria-tetanus-acellular pertussis vaccine</intervention_name>
    <description>0.5 mL, Intramuscular Other Name: DTaP</description>
    <arm_group_label>Vaccine 2B</arm_group_label>
    <arm_group_label>Vaccine 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine</intervention_name>
    <description>0.5 mL, Intramuscular Other Name: PENTAXIM</description>
    <arm_group_label>Vaccine 3C</arm_group_label>
    <arm_group_label>Vaccine 4B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects aged 2months、3months、18-24months and 4-6 years old;

          -  Willing to provide proof of identity;

          -  Able to understand and sign the informed consent by guardians or trustees;

          -  Able and willing comply with the requirements of the protocol by guardians or
             trustees;

          -  Subjects of 2 months age have not been vaccinated with diphtheria, IPV, Hib, or
             13-valent pneumococcal polysaccharide conjugate vaccine;

          -  Subjects of 3 months have not been inoculated with vaccines containing diphtheria,
             Hib, 13-valent pneumococcal polysaccharide conjugate vaccine and Meningococcal Group
             AC Bivalent Meningococcal Conjugate Vaccine;volunteers of 3 months (C3 group) have not
             been inoculated with vaccines containing IPV;

          -  Subjects aged 18-24 months who had completed the immunization program of 3 doses of
             DTaP and had without the fourth DTaP vaccine ;

          -  Subjects aged 4-6 years who have completed the immunization program of 4 doses of DTaP
             or similar vaccines containing DTP component, but who have not received DT vaccine;

        Exclusion Criteria:

          -  Premature birth in infant under 1 year of age (delivery before the 37th week of
             pregnancy)or low birth weight (birth weight&lt; 2300g for girls,&lt;2500g for boys);

          -  History of abnormal labor process or asphyxia rescue ;

          -  Subjects who has a medical history of diphtheria, pertussis or tetanus;

          -  In the past 30 days, individuals who have had contact with individuals with confirmed
             pertussis, diphtheria and tetanus diseases in their families;

          -  Allergic person;

          -  Any prior administration of blood products in last 3 month;

          -  Any prior administration of other research medicines in last 1 month;

          -  Plans to participate in or is participating in any other drug clinical study;

          -  Any prior administration of attenuated live vaccine in last 14 days;

          -  Any prior administration of subunit or inactivated vaccines in last 7 days;

          -  Had fever before vaccination, Subjects with temperature &gt;37.0°C on axillary setting;

          -  According to the investigator's judgment, the subjects have any other factors that
             make them unfit to participate in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Yanxia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Lili</last_name>
    <phone>+8613643826177</phone>
    <email>13643826177@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changge Center for Disease Control and Prevention</name>
      <address>
        <city>Xuchang</city>
        <state>Henan</state>
        <zip>461500</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Lili</last_name>
      <phone>13643826177</phone>
      <email>13643826177@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>DTcP</keyword>
  <keyword>Whooping Cough</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to maintain the rights of the subject, do not open the IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

